Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

– Three Oral Presentations and 30 Posters Across HBV, HCV, HDV, and Fibrosis, Including Late-Breaking Data on Hepcludex® in HDV, Demonstrate Gilead’s Commitment to Addressing Unmet Needs for...

Related Keywords

Foster City ,California ,United States ,Tenofovir Alafenamide ,Clinical Research For Hepatitis ,Risk Of Development ,Gilead Sciences In Liver Disease ,Nasdaq ,Gilead Sciences ,World Health Organization ,Exchange Commission ,Gilead Sciences Inc ,Viruses At Gilead Sciences ,American Association ,Liver Diseases ,European Economic Area ,Liver Meeting ,Anu Osinusi ,Vice President Clinical Research ,Emerging Viruses ,Marketing Authorization ,Combination With Pegylated Interferon ,Patients With Chronic Hepatitis Delta ,Primary Endpoint Results From ,Multicenter Study ,Detected Resistance ,Term Safety ,Sofosbuvir Based Direct Acting Antivirals ,Pediatric Patients ,Hepatitisc Virus ,Complexadic Study ,Elimination Programs Leading ,Global Action ,Kidney Disease Risk ,Advanced Fibrosis Due ,Non Alcoholic Steatohepatitis ,Between Liver Biomarkers ,Clinical Outcomes ,Primary Sclerosing Cholangitis ,Retrospective Real World Study ,Important Safety Information ,Safety Information ,Worsening Renal Impairment ,Severe Hepatomegaly ,During Treatment ,Crcl Hepatic Impairment ,Private Securities Litigation Reform Act ,Quarterly Report ,Gilead Logo ,Markets ,